Specifically, molecular targeted therapeutic drugs, such as inhibitors of VEGF, EGFR, and HER2, play a pivotal role in the management of malignant tumors, with their effectiveness being closely tied to the composition of the intestinal microbiota (Huang et al. 2019). This evidence concerns the gene EGFR and cancer.